Tissue company looks to cardiovascular repair implant
This article was originally published in Clinica
US start-up company Reprogenesis has announced plans to begin Phase I trials of a bioactive vascular repair implant within 12 months. The RP-VAD implant combines allogenic endothelial cells with a polymer matrix and is designed to restore the function of endothelial cells lining vessels which have been damaged during surgery or vascular access procedures.
You may also be interested in...
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.
Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.